EP0831771A2 - Orale verabreichung von genkonstrukten - Google Patents

Orale verabreichung von genkonstrukten

Info

Publication number
EP0831771A2
EP0831771A2 EP96918287A EP96918287A EP0831771A2 EP 0831771 A2 EP0831771 A2 EP 0831771A2 EP 96918287 A EP96918287 A EP 96918287A EP 96918287 A EP96918287 A EP 96918287A EP 0831771 A2 EP0831771 A2 EP 0831771A2
Authority
EP
European Patent Office
Prior art keywords
gene construct
delivery
gene
formulation
therapeutic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96918287A
Other languages
English (en)
French (fr)
Inventor
Peter E. Daddona
Gamil G. De Chadarevian
Joseph A. Fix
Phyllis I. Gardner
Howard B. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of EP0831771A2 publication Critical patent/EP0831771A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • FIG. 3 is a cross-sectional view of a further embodiment of the device of the present invention, the device being in closed or prepared form prior to placement in the environment of use.
  • FIG. 4 is the device of FIG. 3 in operation after activation by placement in the environment of use, showing the device opened to release the gene construct to the environment.
  • the present invention involves delivery of a gene construct to a targeted portion of the Gl tract.
  • Potential portions of the Gl tract that may be targeted include but are not limited to the distal small intestine, the M cells, the Peyer's Patches and the upper colon.
  • Such targeting will promote transduction of gastrointestinal epithelial cells or M cells at the delivery site.
  • devices such as those described below may be taken orally. These devices will retain the gene construct formulation such that delivery into the stomach and upper intestine will be prevented and a bolus dose will be delivered at the target site.
  • the housing 32 may be prepared as a hollow cylinder that is closed at one end.
  • the cylinder may be a water permeable material as described above and coated with an impermeable coating in the portion that contains the gene construct formulation 20.
  • the plug 36 may be a water-swellable material.
  • the device is assembled by preparing an osmotic plug as described above from the expansion agent 40 and the piston 42. This plug is placed into the closed end of the hollow cylinder, with the expansion agent 40 adjacent the closed end of the cylinder.
  • the gene construct formulation is then placed into the housing 32 adjacent the piston 42.
  • the plug 36 is then placed into the open end 34 of the housing 32.
  • the polymeric osmotic formulation has a composition of 60 wt% polyethylene oxide (Polyox® 303, Union Carbide), 29 wt% sodium chloride, 5 wt% polyacrylic acid (Carbomer® 934P, B.F. Goodrich), 5 wt% hydroxypropylmethylcellulose E-5, and 1 wt% ferric oxide.
  • Polyox® 303 Union Carbide
  • 29 wt% sodium chloride 5 wt% polyacrylic acid
  • Carbomer® 934P Polyacrylic acid
  • B.F. Goodrich 5 wt% hydroxypropylmethylcellulose E-5
  • 1 wt% ferric oxide 1 wt% ferric oxide.
  • each of the above components is screened through a 40 mesh screen, and the sized components are added to a mixing vessel in the appropriate proportions.
  • the dry components are mixed thoroughly for 10 minutes; then, SDA 3A ethanol is slowly added while mixing continues until a wet mass is formed.
  • Delivery devices according to the present invention containing non ⁇ viral vector formulations are prepared follows.
  • Liposomes are prepared by the dehydration-rehydration techniques described by Gregoriadis and Panagiotidi (Immunol. Lett. 1989, 20:237-240).
  • Distearolyphosphatidylcholine, hydrogenated phosphatidylse ne and cholesterol in a molar ratio of 1 :1 :2 are dissolved in chloroform/methanol (9:1 v/v).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP96918287A 1995-06-07 1996-06-07 Orale verabreichung von genkonstrukten Withdrawn EP0831771A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47596195A 1995-06-07 1995-06-07
US475961 1995-06-07
PCT/US1996/009371 WO1996040081A2 (en) 1995-06-07 1996-06-07 Oral delivery of gene constructs

Publications (1)

Publication Number Publication Date
EP0831771A2 true EP0831771A2 (de) 1998-04-01

Family

ID=23889916

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96918287A Withdrawn EP0831771A2 (de) 1995-06-07 1996-06-07 Orale verabreichung von genkonstrukten

Country Status (6)

Country Link
EP (1) EP0831771A2 (de)
JP (1) JPH11507340A (de)
KR (1) KR19990022184A (de)
AU (1) AU6097896A (de)
CA (1) CA2221323A1 (de)
WO (1) WO1996040081A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976571A (en) * 1991-01-31 1999-11-02 Port Systems, L.L.C. Method for making a multi-stage drug delivery system
CA2222574A1 (en) * 1995-06-07 1996-12-19 Yale University Oral delivery of adeno-associated viral vectors
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
WO1999030746A1 (en) * 1997-12-12 1999-06-24 Synoptik A/S Container for timed release of substances
EP1140213A1 (de) * 1998-12-14 2001-10-10 Synoptik Holding A/S System zur reinigung von kontaktlinsen
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663725B2 (en) * 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9640081A2 *

Also Published As

Publication number Publication date
CA2221323A1 (en) 1996-12-19
KR19990022184A (ko) 1999-03-25
WO1996040081A2 (en) 1996-12-19
AU6097896A (en) 1996-12-30
WO1996040081A3 (en) 1997-02-20
JPH11507340A (ja) 1999-06-29

Similar Documents

Publication Publication Date Title
US5443459A (en) Osmotic device for delayed delivery of agent
JP3307929B2 (ja) 薬剤の遅延投与のための浸透圧デバイス
US5391381A (en) Dispenser capable of delivering plurality of drug units
CA2352389C (en) An oral formulation for gastrointestinal drug delivery
EP2642978B1 (de) Immunmodulatorische zusammensetzungen mit hydralazin und ciclosporin zur behandlung von gastrointestinalen erkrankungen
AU682703B2 (en) Dosage form for administering drug in liquid formulation
JP2010502759A (ja) タンパク質物質の経口または直腸投与のための医薬組成物
JP2001508815A (ja) カチオン性ポリマー／脂質核酸送達ビヒクル
WO2004026453A2 (en) Microcapsules and methods of use
EP1090645A2 (de) Orale verabreichung von chemischmodifizierten Proteinen
JPH07504401A (ja) 薬物投与の遅延活性化による浸透デバイス
US11479593B2 (en) Compositions, formulations and interleukin production and purification
CN102100912B (zh) 一种给药组合物及其制备和使用方法
EP0831771A2 (de) Orale verabreichung von genkonstrukten
AU1820999A (en) Grafted copolymers as gene carriers
CN102335431B (zh) 一种给药组合物及其制备和使用方法
EP0844004B1 (de) Atelocollagen enthaltende gen-zusammensetzungen
KR19990021985A (ko) 높은 약물 부하량을 갖는 삼투 장치 및 약물 전달의 지연활성화
JP2005508875A (ja) 転座因子として使用するためのペプチド
KR100428273B1 (ko) 약물전달의지연된활성화및완전한약물방출기능을갖는삼투장치
CN1187118A (zh) 经口递送基因构建物
WO2023152223A1 (en) A polymer to increase the bioavailability of a pharmaceutical compound
WO2000016784A1 (fr) Systeme d'administration orale de medicament permettant d'ameliorer la biodisponibilite de la glycyrrhetine activee
Mackay Delivery of therapeutic peptides and proteins
Truong-Le Synthesis, gene transfer properties, and delivery of genetic vaccines using the DNA-gelatin nanospheres

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971202

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000601